|

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

RECRUITINGPhase 2Sponsored by University of California, Irvine
Actively Recruiting
PhasePhase 2
SponsorUniversity of California, Irvine
Started2026-06-18
Est. completion2028-02
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07693452

Summary

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria (complete details available in protocol):

* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS/HIPEC
* Age ≥18 years
* ECOG performance status ≤2

Key Exclusion Criteria (complete details available in protocol):

* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC
* Patients currently taking metformin for another medical indication
* Patients with a prior adverse event to administration of metformin

Conditions3

Appendiceal Mucinous NeoplasmCancerPseudomyxoma Peritonei

Interventions1

Metformin

Locations1 site

Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868
Oliver Eng, MD877-827-8839ucstudy@uci.edu

Find trials near these locations

All trials in California

Related trials

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.